New insights into the role of adipocytes in pancreatic cancer progression: paving the way towards novel therapeutic targets

Theranostics. 2023 Jul 3;13(12):3925-3942. doi: 10.7150/thno.82911. eCollection 2023.

Abstract

Pancreatic cancer (PC) remains one of the most lethal malignancies across the world, which is due to delayed diagnosis and resistance to current therapies. The interactions between pancreatic tumor cells and their tumor microenvironment (TME) allow cancer cells to escape from anti-cancer therapies, leading to difficulties in treating PC. With endocrine function and lipid storage capacity, adipose tissue can maintain energy homeostasis. Direct or indirect interaction between adipocytes and PC cells leads to adipocyte dysfunction characterized by morphological change, fat loss, abnormal adipokine secretion, and fibroblast-like transformation. Various adipokines released from dysfunctional adipocytes have been reported to promote proliferation, invasion, metastasis, stemness, and chemoresistance of PC cells via different mechanisms. Additional lipid outflow from adipocytes can be taken into the TME and thus alter the metabolism in PC cells and surrounding stromal cells. Besides, the trans-differentiation potential enables adipocytes to turn into various cell types, which may give rise to an inflammatory response as well as extracellular matrix reorganization to modulate tumor burden. Understanding the molecular basis behind the protumor functions of adipocytes in PC may offer new therapeutic targets.

Keywords: adipocyte dysfunction; adipokines; fat loss; pancreatic cancer; trans-differentiation; tumor microenvironment.

Publication types

  • Review

MeSH terms

  • Adipocytes* / metabolism
  • Adipokines
  • Adipose Tissue / metabolism
  • Humans
  • Lipids
  • Pancreatic Neoplasms* / pathology
  • Tumor Microenvironment

Substances

  • Adipokines
  • Lipids